French trial opens in diabetes-diet drug scandal

Jacques Servier, center, founder of Servier Laboratories, sits with his lawyers during the opening of the trial at Nanterre's court house, outside Paris, Monday, May 14, 2012. A French court has opened the first of trials over a drug for diabetes commonly used to lose weight and suspected of killing at least 500 people. The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine, benfluorex _ removed from the market in 2009 after being found to thicken heart valves. (AP Photo/Michel Euler)

(AP) -- The first French trial has begun over a diabetes drug that was also used to lose weight and is suspected in the deaths of at least 500 people.

The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine called - which was taken off the market in 2009 after being found to thicken .

However, another investigation is underway and lawyers for Servier were arguing Monday against holding the current trial claiming that the laboratory could be judged twice on the same grounds.

The nature of benfluorex was allegedly hidden to obtain approval for the drug, first marketed in 1976. So far, charges have been filed against seven people, including drugmaker chief Jacques Servier.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Pyridoxine-doxylamine drug safety data lacking

9 hours ago

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

FDA approves new type 2 diabetes drug

Apr 15, 2014

(HealthDay)—Millions of Americans with type 2 diabetes have a new treatment option with the U.S. Food and Drug Administration's approval Tuesday of a once-weekly injectable drug, Tanzeum.

User comments